AI assistant
Evotec SE — M&A Activity 2012
Dec 17, 2012
151_rns_2012-12-17_e5adbdf1-7242-4ba2-b6d9-167248cb870c.html
M&A Activity
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 17 December 2012 09:08
Evotec AG: Evotec announces NMDA antagonist license agreement
Evotec AG / Key word(s): Alliance
17.12.2012 09:08
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
- December 2012
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into
a license agreement with Janssen Pharmaceuticals, Inc. ('Janssen')
regarding its NR2B subtype selective NMDA-antagonist portfolio for
development against diseases in the field of depression.
Under the terms of this agreement Janssen has been granted an exclusive,
worldwide license to a series of small molecule drug candidates. Evotec
will receive an upfront payment of USD 2 million with an additional USD 6
million to be paid upon confirmation of certain pre-clinical properties of
the candidates. Evotec is eligible to receive additional milestone payments
from Janssen upon the successful completion of certain clinical, regulatory
and launch events for a first product, which may total up to USD 67
million, as well as additional, reduced milestone payments upon successful
completion of certain events for additional indications and/or compounds.
Evotec shall be entitled to receive an additional USD 100 million in
commercial milestones depending and upon meeting certain sales thresholds
and royalties which could be as high as double-digit on certain future
sales of royalty bearing products. Evotec will share portions of the
payments with F. Hoffmann-La Roche Ltd., which originally discovered the
molecules.
Contact: Dr Mario Polywka, Chief Operating Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +44 (0)1235
441676, [email protected]
17.12.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service